The CML Advocates Network's Clinical Trials Registry currently lists 27 CML studies

Set up and driven by CML Advocates Network, the Clinical Trials Registry provides patients with easy access to information on ongoing CML studies. Entries are updated at regular intervals: new studies and sites are added whereas completed or terminated studies are no longer shown on the registry. Currently 27 CML studies from many countries around the world are listed. The most recent additions to the registry are:

  • OPTIC, a study to determine the efficacy and safety of ponatinib in patients with resistant CML in chronic phase. This study is including patients in 19 countries on five continents.
  • ENESTPath Patient’s Voice Italian Substudy. This study is exploring the emotional experience of patients participating in the ENESTPath study with nilotinib. The substudy is available only in Italy.

Eleven studies are ongoing but no longer recruiting new patients. These studies have been moved to the category "Trials that are no longer recruiting".Two trials have been completed or terminated: Spirit 3 and NordDutchCML006. They are no longer ongoing and therefore not any more listed on the database.

We would like to thank everyone for sharing information with us on new studies or changes in ongoing studies. Your invaluable input helps us keep the registry up to date. Thank you.

Do you know of any study that is not yet listed in our Clinical Trial Database? Please let us know by filling out this form. Or is there an entry which should be corrected? If so, please send us an email. Please also visit our discussion forum if you have any questions or wish to share your experience on these studies!


Please donate!

Please donate!


Tweet Feed

From 26 April “Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chron……

Retweeted Saturday, 19 May 2018

Progress is impossible without change and those who cannot change their minds cannot change anything... 🤔…

Retweeted Sunday, 13 May 2018

Encuesta Parada de tratamiento #TFR4CML En #CMLHZ18 vimos primeros resultados sobre 600 respuestas ya recibidas a l……

Retweeted Wednesday, 09 May 2018